MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: Knowing that the PI3K/AKT/mTOR pathway is hyperactive in CML, indirect suppression of mTOR function by modulation of the AMPK pathway was proposed as an alternative therapeutic approach to overcome TKI resistances.